4 - Enliven Therapeutics, Inc. (0001672619) (Issuer)

4 - Enliven Therapeutics, Inc. (0001672619) (Issuer)

4 - Enliven Therapeutics, Inc. (0001672619) (Issuer)

4 - Enliven Therapeutics, Inc. (0001672619) (Issuer)

4 - Enliven Therapeutics, Inc. (0001672619) (Issuer)

4 - Enliven Therapeutics, Inc. (0001672619) (Issuer)

4 - Enliven Therapeutics, Inc. (0001672619) (Issuer)

4 - Enliven Therapeutics, Inc. (0001672619) (Issuer)

4 - Enliven Therapeutics, Inc. (0001672619) (Issuer)

4 - Enliven Therapeutics, Inc. (0001672619) (Issuer)

Reported cumulative MMR rate of 47% (25 of 53) by 24 weeks with 32% (13 of 41) of patients achieving MMR by 24 weeks, which continues to compare favorably to precedent Phase 1 trials of approved BCR::ABL1 TKIs ELVN-001 continues to demonstrate a favorable safety and tolerability profile across all dose levels with 90 patients enrolled and a median treatment duration of ~29 weeks at cutoff Enliven will host a webcast and conference call today, June 13, at 1:30 p.m. ET BOULDER, Colo., June 13, 2025 /PRNewswire/ -- Enliven Therapeutics, Inc. (Enliven or the Company) (NASDAQ:ELVN), a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutic

Updated data from the Phase 1 ENABLE clinical trial of ELVN-001 in CML to be presented at the EHA 2025 Congress in June EHA abstract reported cumulative MMR rate of 44% (16 of 36) by 24 weeks with 26% (7 of 27) of patients achieving MMR by 24 weeks, and ELVN-001 remains well-tolerated with 74 patients enrolled Enliven to host a webcast and conference call following the oral presentation at EHA on Friday, June 13, at 1:30 p.m. ET Strong balance sheet with $290 million in cash, cash equivalents and marketable securities, which is expected to provide cash runway into late 2027 BOULDER, Colo., May 14, 2025 /PRNewswire/ -- Enliven Therapeutics, Inc. (Enliven or the Company) (NASDAQ:ELVN), a clini

Reported cumulative MMR rate of 44% (16 of 36) by 24 weeks with 26% (7 of 27) of patients achieving MMR by 24 weeks, which continues to compare favorably to precedent Phase 1 trials of approved BCR::ABL1 TKIs ELVN-001 continues to demonstrate a favorable safety and tolerability profile across all dose levels with 74 patients enrolled and a median treatment duration of ~26 weeks at cutoff Presentation at EHA will include updated data with additional patients and longer treatment duration Enliven will host a webcast and conference call on June 13 at 1:30 p.m. ET BOULDER, Colo., May 14, 2025 /PRNewswire/ -- Enliven Therapeutics, Inc. (Enliven or the Company) (NASDAQ:ELVN), a clinical-stage bi

BOULDER, Colo., April 09, 2024 (GLOBE NEWSWIRE) -- Enliven Therapeutics, Inc. (Enliven or the Company) (NASDAQ:ELVN), a clinical-stage precision oncology company focused on the discovery and development of next-generation small molecule kinase inhibitors, today announced the appointment of Lori Kunkel, MD, to its Board of Directors. Dr. Kunkel brings more than twenty-five years of experience in oncology and immunology drug development and commercialization to the Board. "Lori has served as scientific advisor to Enliven since its inception, and we are delighted to now welcome her to our Board," said Sam Kintz, MBA, Enliven's Co-founder and Chief Executive Officer. "She brings a wealth of e

BOULDER, Colo., June 16, 2025 /PRNewswire/ -- Enliven Therapeutics, Inc. (Enliven or the Company) (NASDAQ:ELVN), a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics, today announced that it has closed its underwritten public offering of 9,920,987 shares of its common stock, which includes the full exercise of the underwriters' option to purchase 1,526,250 additional shares of its common stock, at a price to the public of $19.66 per share and, in lieu of common stock to certain investors, pre-funded warrants to purchase 1,780,263 shares of its common stock at a price to the public of $19.659 per pre-funded warrant, which represent

BOULDER, Colo., June 13, 2025 /PRNewswire/ -- Enliven Therapeutics, Inc. (Enliven or the Company) (NASDAQ:ELVN), a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics, today announced that it has priced its previously announced underwritten public offering of 8,394,737 shares of its common stock at a price to the public of $19.66 per share and, in lieu of common stock to investors who so choose, pre-funded warrants to purchase up to 1,780,263 shares of Enliven's common stock at a price to the public of $19.659 per pre-funded warrant, which represents the per share public offering price of each share of Enliven's common stock less t

BOULDER, Colo., June 13, 2025 /PRNewswire/ -- Enliven Therapeutics, Inc. (Enliven or the Company) (NASDAQ:ELVN), a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics, today announced that it has commenced an underwritten public offering of $200 million of shares of its common stock and, in lieu of common stock to investors who so choose, pre-funded warrants to purchase shares of Enliven's common stock. In addition, Enliven intends to grant the underwriters a 30-day option to purchase up to an additional $30 million of shares of its common stock. All of the shares of common stock and pre-funded warrants are being offered by Enliven

Reported cumulative MMR rate of 47% (25 of 53) by 24 weeks with 32% (13 of 41) of patients achieving MMR by 24 weeks, which continues to compare favorably to precedent Phase 1 trials of approved BCR::ABL1 TKIs ELVN-001 continues to demonstrate a favorable safety and tolerability profile across all dose levels with 90 patients enrolled and a median treatment duration of ~29 weeks at cutoff Enliven will host a webcast and conference call today, June 13, at 1:30 p.m. ET BOULDER, Colo., June 13, 2025 /PRNewswire/ -- Enliven Therapeutics, Inc. (Enliven or the Company) (NASDAQ:ELVN), a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutic

BOULDER, Colo., May 22, 2025 /PRNewswire/ -- Enliven Therapeutics, Inc. (Enliven or the Company) (NASDAQ:ELVN), a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics, today announced that management will present at the following investor conferences: TD Cowen's 6th Annual Oncology Innovation Summit: Insights from ASCO & EHAFormat: Fireside ChatDate: Tuesday, May 27, 2025Time: 1:00 p.m. ET Jefferies Global Healthcare ConferenceFormat: Fireside ChatDate: Wednesday, June 4, 2025Time: 4:20 p.m. ET Goldman Sachs Annual Global Healthcare ConferenceFormat: Fireside ChatDate: Tuesday, June 10, 2025Time: 4:00 p.m. ET The fireside chats will

Updated data from the Phase 1 ENABLE clinical trial of ELVN-001 in CML to be presented at the EHA 2025 Congress in June EHA abstract reported cumulative MMR rate of 44% (16 of 36) by 24 weeks with 26% (7 of 27) of patients achieving MMR by 24 weeks, and ELVN-001 remains well-tolerated with 74 patients enrolled Enliven to host a webcast and conference call following the oral presentation at EHA on Friday, June 13, at 1:30 p.m. ET Strong balance sheet with $290 million in cash, cash equivalents and marketable securities, which is expected to provide cash runway into late 2027 BOULDER, Colo., May 14, 2025 /PRNewswire/ -- Enliven Therapeutics, Inc. (Enliven or the Company) (NASDAQ:ELVN), a clini

Reported cumulative MMR rate of 44% (16 of 36) by 24 weeks with 26% (7 of 27) of patients achieving MMR by 24 weeks, which continues to compare favorably to precedent Phase 1 trials of approved BCR::ABL1 TKIs ELVN-001 continues to demonstrate a favorable safety and tolerability profile across all dose levels with 74 patients enrolled and a median treatment duration of ~26 weeks at cutoff Presentation at EHA will include updated data with additional patients and longer treatment duration Enliven will host a webcast and conference call on June 13 at 1:30 p.m. ET BOULDER, Colo., May 14, 2025 /PRNewswire/ -- Enliven Therapeutics, Inc. (Enliven or the Company) (NASDAQ:ELVN), a clinical-stage bi

BOULDER, Colo., April 2, 2025 /PRNewswire/ -- Enliven Therapeutics, Inc. (Enliven or the Company) (NASDAQ:ELVN), a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics, today announced the Company will present five posters at the upcoming American Association for Cancer Research (AACR) Annual Meeting, taking place April 25-30, 2025, in Chicago, Illinois. Poster Presentation Details  Abstract 4712 – ELVN-002, a potent, selective HER2 inhibitor with a differentiated binding mode conferring the potential for enhanced efficacy in combination with HER2-targeting antibody-drug conjugates Date/Time: Tuesday, April 29, 2025, 9:00 a.m. – 12:

Updated Phase 1 data for ELVN-001 expected mid-2025 as positive enrollment momentum continues Expected monotherapy and combination data from the ELVN-002 Phase 1 trials in second half of 2025 Strong balance sheet with $313 million in cash, cash equivalents and marketable securities, which is expected to provide cash runway into mid-2027 BOULDER, Colo., Mar. 13, 2025 /PRNewswire/ -- Enliven Therapeutics, Inc. (Enliven or the Company) (NASDAQ:ELVN), a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics, today reported financial results for the fourth quarter and full year ended December 31, 2024, and provided a business update, inclu

BOULDER, Colo., Feb. 25, 2025 /PRNewswire/ -- Enliven Therapeutics, Inc. (Enliven or the Company) (NASDAQ:ELVN), a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics, today announced that management will participate in a fireside chat at the TD Cowen 45th Annual Health Care Conference on Tuesday, March 4, 2025, at 10:30 a.m. ET. The fireside chat will be webcast live and can be accessed by visiting the investor relations section of the Company's website at https://ir.enliventherapeutics.com/. The webcast will be archived for a period of 90 days following the conclusion of the live event. About Enliven TherapeuticsEnliven is a clin

144 - Enliven Therapeutics, Inc. (0001672619) (Subject)

SCHEDULE 13D/A - Enliven Therapeutics, Inc. (0001672619) (Subject)

8-K - Enliven Therapeutics, Inc. (0001672619) (Filer)

424B5 - Enliven Therapeutics, Inc. (0001672619) (Filer)

S-3MEF - Enliven Therapeutics, Inc. (0001672619) (Filer)

424B5 - Enliven Therapeutics, Inc. (0001672619) (Filer)

8-K - Enliven Therapeutics, Inc. (0001672619) (Filer)

10-Q - Enliven Therapeutics, Inc. (0001672619) (Filer)

8-K - Enliven Therapeutics, Inc. (0001672619) (Filer)

DEFA14A - Enliven Therapeutics, Inc. (0001672619) (Filer)

Goldman initiated coverage of Enliven Therapeutics with a rating of Buy and set a new price target of $37.00

BTIG Research initiated coverage of Enliven Therapeutics with a rating of Buy and set a new price target of $42.00

H.C. Wainwright initiated coverage of Enliven Therapeutics with a rating of Buy and set a new price target of $37.00

Robert W. Baird initiated coverage of Enliven Therapeutics with a rating of Outperform and set a new price target of $32.00

Mizuho initiated coverage of Enliven Therapeutics with a rating of Buy and set a new price target of $34.00

Jefferies initiated coverage of Enliven Therapeutics with a rating of Buy and set a new price target of $27.00

TD Cowen initiated coverage of Enliven Therapeutics with a rating of Outperform

SC 13G/A - Enliven Therapeutics, Inc. (0001672619) (Subject)

SC 13G/A - Enliven Therapeutics, Inc. (0001672619) (Subject)

SC 13G/A - Enliven Therapeutics, Inc. (0001672619) (Subject)

SC 13G/A - Enliven Therapeutics, Inc. (0001672619) (Subject)

SC 13G/A - Enliven Therapeutics, Inc. (0001672619) (Subject)

SC 13G - Enliven Therapeutics, Inc. (0001672619) (Subject)

SC 13D/A - Enliven Therapeutics, Inc. (0001672619) (Subject)

SC 13D/A - Enliven Therapeutics, Inc. (0001672619) (Subject)

SC 13D/A - Enliven Therapeutics, Inc. (0001672619) (Subject)

SC 13D/A - Enliven Therapeutics, Inc. (0001672619) (Subject)